AGA’s newest on-demand offering on the topic of biosimilars, AGA Expert Exchange: Biosimilars in GI, is now available.
The introduction of biologic therapies in 1998 helped revolutionize the treatment of inflammatory bowel disease. However, biologic therapy is costly and one of the largest contributors to direct medical costs in IBD. Now, many of these biologics have come off patent or will soon come off patent. This has provided drug manufacturers with the incentive and opportunity to develop biosimilars to compete with existing biologics thereby benefitting health care providers and patients by increasing treatment options and improving access to important medicines at lower costs.
Unfortunately, there is still a great deal of skepticism about the safety and efficacy of biosimilars even if there is sufficient evidence demonstrating that there are no significant concerns related to the safety and purity of FDA-approved biosimilars, nor is there an increased loss of response nor increased immunogenicity after transitioning to the biosimilar.
Let’s change that. Learn more about biosimilars and how to appropriately incorporate them into your practice today. Access AGA Expert Exchange: Biosimilars in GI today.
This is supported by an independent grant from Amgen Inc.
For even more AGA education on biologics, take advantage of the four-part panel series Biosimilars: How to Make the Switch, which demonstrates the safety and efficacy of biosimilars in different clinical settings.
